[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burns-and-scalds\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burns-and-scalds":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652317","nurse-led-aromatherapy-100652317",false,"NCT07773181","Nurse Led Aromatherapy","Inclusion Criteria:\n\n* Seen in outpatient burn center\n* Burns not covering more than 7.5% of body surface area\n* First burn dressing change\n* Second degree burns\n* Scalding, flame, or contact burns\n\nExclusion Criteria:\n\n* Allergy\u002Fhypersensitivity to essential oils, or any components of the aromatherapy formula\n* Airway\u002Fhypersensitivity to fragrances, paint fumes, or turpentine\n* Respiratory conditions (e.g. asthma, reactive airway disease, recent wheezing)\n* Inhalation injury\n\n  1. Thermal injury: Caused by direct thermal damage which affects upper airways resulting in edema, stridor and upper airway obstruction\n  2. Chemical injury to airways and lung parenchyma from products of combustion\n  3. Systemic poisoning from carbon monoxide and\u002For cyanide\n* Surgery for burn\n* Infection of burn\n* Burns of the face\n* Burns requiring Acticoat dressing\n* Delayed burns (those that have been previously treated outside of the hospital, but have not healed and require further treatment)","ALL","2 Months","7 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this trial is to see if aromatherapy in addition to pain medication, will help manage pain in pediatric burn patients during their first burn dressing change. Participants aged 2 months to 7 years old will be randomly assigned to usual care (pain medication only) or to receive aromatherapy in addition to pain medication prior to their first burn dressing change. The main question it aims to answer is:\n\n-Does aromatherapy plus pain medication decrease pain more than pain medication alone for young children receiving their first burn dressing change?\n\nAll participants will receive the standard pain medications and have their pain assessed on medication administration (prior to aromatherapy for the intervention group), prior to dressing change (after aromatherapy for the intervention group), and 15 minutes after the dressing change is complete.\n\nOnce the final pain assessment is complete, there is no more information needed from participants for the purposes of the study. All participants will continue to follow up in the clinic for the remaining dressing changes as needed.",[26],"Burns and Scalds",[28,29,30,31],"aromatherapy","burns","child","infant","NOT_YET_RECRUITING","2026-08-16",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":20},"2026-09",{"date":40,"type":20},"2028-07",{"name":42,"class":43},"KK Women's and Children's Hospital","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100616968","multicenter-randomized-non-inferiority-study-to-compare-the-performance-and-safety-of-debrisoft-duo-with-debrisoft-pad-in-the-debridement-of-wounds-100616968","NCT07312513","Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient is legally capable\n* Patient has signed written informed consent\n* Presence of one of the following wounds\n\n  * Venous lower leg ulcer\n  * Arterial ulcer\n  * Diabetic ulcer\n  * Pressure ulcer\n  * Post-operative wound healing by secondary intention\n  * Traumatic wound\n  * Surgical wound\n  * Burn or scald (grade III: after surgical debridement)\n  * Epidermolysis Bullosa\n* Wound area \\>4cm2\n* The entire wound area can be displayed on one photo from a distance of 25-30 cm\n* Covered with at least 30% debris, necrosis, slough, fibrotic tissue\n\nExclusion Criteria:\n\n* Known allergy and\u002For hypersensitivity to Debrisoft® Duo or any of the product components\n* Pregnancy or breast feeding\n* Patient is illiterate\n* Participation in a interventional clinical trial within the last 14 days and during participation in this study\n* Any other medical condition, which, by opinion of the investigator, may have impact of the success of the study treatment and\u002F or interpretation of the study results\n* severe pain or hyperesthesia in the wound area\n* history of drug or alcohol abuse\n* chronic analgesic use (especially opioids) that could influence baseline pain perception\n* cognitive impairment, which may affect the ability to accurately self-report pain\n* Use of anaesthesia before the debridment procedure\n* presence of hard necrotic tissue or other tissue which should not be debrided in general. Other types of hard necrotic tissue requiring debridement, as determined by the investigator, are permitted and may be also pre-moistened before the procedure if deemed necessary","18 Years",{"count":53,"type":20},104,[23],"The aim of this post market clinical follow up (PMCF) study is to confirm the performance of Debrisoft® Duo, to collect safety data regarding expected adverse events and to detect potential unexpected adverse events associated with the use of Debrisoft® Duo within the certified indications and under the conditions of routine use.",[57,58,59,60,61,26,62,63,64],"Diabetic Ulcers","Arterial Ulcers","Venous Ulcers","Pressure Ulcers","Postoperative Wounds Healing by Secondary Intention","Epidermolysis Bullosa (EB)","Traumatic Wounds","Surgical Wounds",[66,67],"Debridement","mechanical debridement","RECRUITING","2025-12-17",{"date":71,"type":36},"2025-12-31",{"date":73,"type":36},"2025-05-09",{"date":75,"type":20},"2026-02",{"name":77,"class":78},"Lohmann & Rauscher","INDUSTRY",5]